Research Article
Multicenter Study of the Hemorrhage Risk after Endoscopic Mucosal Resection Associated with Direct Oral Anticoagulants
Table 3
Details of DOAC patients with POH after endoscopic mucosal resection.
| | No. | Age (years) | Sex | Tumor location | Tumor size (mm) | Morphology (polypoid/nonpolypoid) | DOAC | Coprescription with antiplatelet | Histology | Number of POH | Hemorrhage date (day) | Nature of hemorrhage |
| | 1 | 75 | M | T | 20 | Polypoid | Rivaroxaban | No | Ad | 2 | 1 and 4 | Apparent bleeding | | 2 | 68 | M | R | 20 | Nonpolypoid | Apixaban | No | HGD | 1 | 6 | Apparent bleeding | | 3 | 76 | M | T | 25 | Polypoid | Apixaban | No | HGD | 2 | 2 and 3 | Apparent bleeding | | 4 | 88 | M | S | 12 | Nonpolypoid | Rivaroxaban | No | HGD | 1 | 10 | Apparent bleeding | | 5 | 70 | M | A | 4 | Polypoid | Dabigatran | No | Ad | 1 | 6 | Apparent bleeding |
|
|
DOAC: direct oral anticoagulant; POH: postoperative hemorrhage; M: male; F: female; T: transverse colon; R: rectum; S: sigmoid colon; A: ascending colon; Ad: low-grade adenoma; HGD: high-grade dysplasia.
|
